Qubit Pharmaceuticals
Qubit Pharmaceuticals is a drug discovery company that utilizes quantum physics and artificial intelligence to design novel drug candidates for major diseases. Their proprietary ATLAS platform, developed over 30 years of research, offers high-precision molecular simulation and modeling, reducing drug candidate selection and optimization time by half and decreasing experimental validation needs tenfold. The company focuses on oncology, inflammation, and pandemic response, with a pipeline of fully owned and partnered programs. Their team of over 60 experts is based in Paris, Boston, and Chicago, with founders leading world-renowned quantum labs. They aim to shift the drug discovery paradigm from 'drug hunting' to 'drug farming'.
Qubit Pharmaceuticals
Qubit Pharmaceuticals is a drug discovery company that utilizes quantum physics and artificial intelligence to design novel drug candidates for major diseases. Their proprietary ATLAS platform, developed over 30 years of research, offers high-precision molecular simulation and modeling, reducing drug candidate selection and optimization time by half and decreasing experimental validation needs tenfold. The company focuses on oncology, inflammation, and pandemic response, with a pipeline of fully owned and partnered programs. Their team of over 60 experts is based in Paris, Boston, and Chicago, with founders leading world-renowned quantum labs. They aim to shift the drug discovery paradigm from 'drug hunting' to 'drug farming'.
TL;DR
Founded: 2020
Headquarters / Offices: Paris (headquarters); Boston and Chicago (U.S. presence)
Core technology: ATLAS platform: quantum physics + AI for high-precision molecular simulation
Therapeutic focus: Oncology, inflammation, antivirals/pandemic response
Team size: ~60 employees
Company Overview
Problem Domain
Drug discovery and molecular simulation for therapeutics (oncology, inflammation, antivirals).
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
Grant listed on company profiles/Crunchbase
Seed round date listed on company profiles/Crunchbase
4500000
Company announced a €4.5M investment program; Bpifrance committed €2M under national programs
Investor Signal
“European Innovation Council; Omnes Capital; Octave Klaba; Quantonation; XAnge; Bpifrance”